CSPC Innovation Pharmaceutical Co Ltd SZSE:300765:
SAYS CO PLANS TO SEEK HONG KONG LISTING
CSPC Innovation Pharmaceutical Plans To Seek Hong Kong Listing
CSPC Innovation Pharmaceutical Co., Ltd. on 6ix
Earlier from CSPC Innovation Pharmaceutical
- CSPC Innovation Pharmaceutical: Revenue up, but net loss driven by R&D surge; biopharma growth and global deals highlight H1
- CSPC Innovation Pharmaceutical: Revenue fell and losses widened in Q1 2025 amid R&D surge and raw material price drops
- CSPC Innovation Pharmaceutical: Net profit plunged 87.63% as R&D spending rose and caffeine prices dropped, but biopharma sales soared 153%
- CSPC Innovation Pharmaceutical: Revenue and profit fell significantly amid market headwinds and rising R&D costs
- CSPC Innovation Pharmaceutical: Revenue and profit fell, but expansion into biologics and new drug launches signal future growth
Later from CSPC Innovation Pharmaceutical
- CSPC Innovation Pharmaceutical: Revenue up 7.71% but net loss deepens; biopharma focus strengthened by Jushi stake buy
- CSPC Innovation Submits Listing Application To Hong Kong Stock Exchange
- CSPC Innovation Pharmaceutical: Revenue rose but higher R&D and lower margins led to a net loss; biopharma growth was strong
- CSPC Innovation Pharmaceutical: Q1 revenue up 40.82% year-over-year, but net loss widened on higher R&D and FX losses
Follow CSPC Innovation Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Innovation Pharmaceutical